Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8...

Hepatic stellate cells (HSCs) and their derived cancer-associated fibroblasts (CAFs) are integral to the development, progression, and prognosis of hepatocellular carcinoma (HCC). However, the mechanisms underlying the transformation of HSCs into CAFs and their subsequent roles in HCC remain incompletely understood. The expression of METTL3 was analyzed in fibroblasts infiltrating into human HCC specimens compared with adjacent nontumor tissues. The effects of HSC-specific METTL3 deficiency on HCC were analyzed by orthotopically implanting hepatoma cells into the fibrotic mouse livers, as well as through direct and indirect co-culture systems. We found that the expression of METTL3, the methyltransferase responsible for RNA N6-methyladenosine (m6A) modification, was downregulated in fibroblasts infiltrating into HCC compared with that of adjacent nontumor tissues. Orthotopical implantation of HCC cells in the fibrotic liver showed that HSC-specific METTL3 deficiency significantly increased tumor burden. Furthermore, conditioned medium treatment and mixed coculture confirmed that METTL3 deletion in HSCs promoted HCC proliferation and migration in vitro, demonstrating that METTL3 deficiency in HSCs accelerated HCC progression in the fibrotic liver. Mechanistically, METTL3 deficiency reduced m6A modification and expression of bone morphogenetic protein 10 (BMP10), a known tumor suppressor. Similar to the effects of METTL3 deficiency, BMP10 knockdown also promoted hepatoma cell growth, whereas recombinant BMP10 (rBMP10) inhibited it. Notably, BMP10 overexpression or rBMP10 supplementation effectively mitigated the tumor-promoting effects of METTL3-deficient HSCs. BMP10's effects were mediated through SMAD1/5/8 phosphorylation. Collectively, our study reveals a novel crosstalk between HSCs and hepatoma cells via the METTL3/m6A-BMP10-SMAD1/5/8 axis, highlighting a potential therapeutic target for HCC.

In this study, we found that HSC-specific METTL3 deficiency significantly accelerated HCC progression in the fibrotic liver. Mechanistically, METTL3 deficiency reduced m6A modification and expression of BMP10 and the downstream SMAD1/5/8 phosphorylation. This study reveals a novel crosstalk between HSCs and hepatoma cells, suggesting a potential therapeutic target for HCC.